MX2014015986A - Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. - Google Patents

Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.

Info

Publication number
MX2014015986A
MX2014015986A MX2014015986A MX2014015986A MX2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A
Authority
MX
Mexico
Prior art keywords
cell
malignant cancers
lymphoma
cell malignant
treating lymphoma
Prior art date
Application number
MX2014015986A
Other languages
English (en)
Inventor
Francesco Bertoni
Paola Bonetti
Original Assignee
Oncoethix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Gmbh filed Critical Oncoethix Gmbh
Publication of MX2014015986A publication Critical patent/MX2014015986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Un método para tratar cánceres malignos de células B o cánceres malignos de células T mediante la administración a un paciente de una cantidad farmacéuticamente aceptable de una composición que comprende (S)-2-[4-(4-clorofenll)-2,3,9-trimetll-6H-tieno[3,2-f][1 ,2,4]triazolo-[4,3-a][1,4]diazepin-6-il]-N-4-hidroxifenil)acetami da; los cánceres malignos de células B incluyen linfoma de células B grandes difusas y linfoma esplénico de zonas marginales; los cánceres malignos de células T incluyen linfoma de células T grandes anaplásticas.
MX2014015986A 2012-06-25 2013-06-25 Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. MX2014015986A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US201261670918P 2012-07-12 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
MX2014015986A true MX2014015986A (es) 2016-02-11

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015986A MX2014015986A (es) 2012-06-25 2013-06-25 Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.

Country Status (12)

Country Link
US (1) US20140018353A1 (es)
EP (1) EP2863923B1 (es)
JP (1) JP6265979B2 (es)
KR (1) KR20150045423A (es)
CN (1) CN105050605A (es)
AU (1) AU2013283378B2 (es)
BR (1) BR112014032105A2 (es)
CA (1) CA2877434A1 (es)
IN (1) IN2014DN11269A (es)
MX (1) MX2014015986A (es)
RU (1) RU2659171C2 (es)
WO (1) WO2014001356A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736569A (zh) 2012-01-12 2015-06-24 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
UA119848C2 (uk) 2013-03-15 2019-08-27 Інсайт Холдинґс Корпорейшн Трициклічні гетероцикли як інгібітори білків бет
US9290514B2 (en) 2013-07-08 2016-03-22 Incyte Holdings Corporation Tricyclic heterocycles as BET protein inhibitors
EP3027194A1 (en) * 2013-08-01 2016-06-08 Oncoethix GmbH Pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
US20160158246A1 (en) * 2013-08-06 2016-06-09 Oncoethix Gmbh Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
KR20160079823A (ko) 2013-11-27 2016-07-06 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 제약 제제를 사용하여 백혈병을 치료하는 방법
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EA039678B1 (ru) 2014-04-23 2022-02-24 Инсайт Корпорейшн 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
JP2017514907A (ja) * 2014-05-02 2017-06-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いる耐性非ホジキンリンパ腫、髄芽腫及び／又はａｌｋ＋非小細胞肺癌の治療方法
WO2015168621A1 (en) 2014-05-02 2015-11-05 Oncoethix Sa Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
WO2015169951A1 (en) 2014-05-08 2015-11-12 Oncoethix Gmbh Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
KR20170016858A (ko) 2014-06-13 2017-02-14 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용하는 비소세포성 폐암 및/또는 소세포성 폐암의 치료 방법
KR20170037670A (ko) 2014-08-19 2017-04-04 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법
TWI712603B (zh) 2014-09-15 2020-12-11 美商英塞特公司 作為ｂｅｔ蛋白抑制劑之三環雜環
KR101675984B1 (ko) * 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
CA2979070A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
PT3472157T (pt) 2016-06-20 2023-05-30 Incyte Corp Formas sólidas cristalinas de um inibidor bet
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
CN112262134B (zh) 2018-04-13 2024-05-24 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006802A1 (en) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
DE69717160T2 (de) * 1996-09-13 2003-05-08 Mitsubishi Pharma Corp Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
EP2239264A4 (en) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
CN104311562B (zh) * 2010-05-14 2017-07-04 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors

Also Published As

Publication number Publication date
JP6265979B2 (ja) 2018-01-24
RU2015101106A (ru) 2016-08-10
RU2659171C2 (ru) 2018-06-28
AU2013283378A1 (en) 2015-01-29
WO2014001356A1 (en) 2014-01-03
KR20150045423A (ko) 2015-04-28
JP2015531747A (ja) 2015-11-05
IN2014DN11269A (es) 2015-10-09
CN105050605A (zh) 2015-11-11
BR112014032105A2 (pt) 2017-08-01
AU2013283378B2 (en) 2017-07-13
EP2863923B1 (en) 2019-05-08
CA2877434A1 (en) 2014-01-03
EP2863923A1 (en) 2015-04-29
US20140018353A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
MX2014015986A (es) Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
PH12016502354A1 (en) Pharmaceutical composition
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
NZ726488A (en) Compositions and methods for transmucosal absorption
MX2013010770A (es) Tratamiento de tumores solidos.
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
MX2010003815A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2.
MX347765B (es) Inhibidores macrociclicos de la quinasa flt3.
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014013090A (es) Derivados de pirrolotriazinona.
MX362939B (es) Derivados de (aza-)isoquinolinona.
PH12015501088A1 (en) Dimeric compounds
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MD4538B1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.